March 27th 2025
Lucas Berenbrok, PharmD, MS, discussed pharmacy deserts and how closures around the US have the potential to impact public health.
February 26th 2025
FDA, DOJ Launch Multi-Agency Task Force to Address Illegal E-Cigarettes
June 11th 2024The new task force highlights a stronger government focus on curbing the risks of e-cigarettes for young people, especially after sustained calls for stricter action on the public health issue by lawmakers and the public.
Tianeptine Misuse Raises Concerns Across US, but is Stigmatizing the Drug Helpful?
May 21st 2024Unregulated tianeptine, often referred to as “gas station heroin,” has led to serious adverse effects. But while health officials warn the public about its potential dangers, others are concerned stigmatization could ruin any future chance of the drugs medicinal use.
Post–COVID-19 Condition: The Frustrating Fight for Recognition and Treatment
May 20th 2024Health care providers must listen to patients who voice their experiences with post–COVID-19 condition symptoms. Only then can a clearer picture of the condition emerge for the millions of patients who have the near-invisible disease.
Exploring Challenges, Opportunities for Community Pharmacists in Tobacco Cessation
April 24th 2024By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.
Exploring the Role of Pharmacists as Facilitators of Harm Reduction Resources
April 1st 2024According to Anita Jacobson, PharmD, pharmacists should actively facilitate access to harm reduction programs by providing information and resources, ensuring the person who uses drugs doesn’t have to navigate the landscape on their own.
Pharmacists Should Adapt Harm Reduction Efforts to Address Unregulated Substances
April 1st 2024It’s important that pharmacists continuously revise their counseling as new information about substances such as xylazine, levamisole, and phenacetin emerges, said Anita Jacobson at this year’s American Pharmacists Association Annual Meeting & Exposition.